ASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (audio)
- Author
- cancerGRACE - H. Jack West, MD
- Published
- Tue 11 Sep 2012
- Episode Link
- http://cancergrace.libsyn.com/asco-2012-lc-highlights-dr-joel-neal-on-the-mek-inhibitor-selumetinib-in-kras-mutation-positive-nsclc-audio
Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).
